Individualizing Discharge and Transitional Care Plans for Patients with COPD Following Hospital Stays

Release date: October 31, 2014
Expiration date: October 31, 2015


Joshua LaBrin, MD
Assistant Clinical Professor
Internal Medicine
University of Utah School of Medicine
Salt Lake City, Utah

Program Overview

Although chronic obstructive pulmonary disease (COPD) is a treatable disease in its early stages, most individuals experience progressive loss of lung function that leads to more frequent and severe symptoms, as well as more frequent and severe exacerbations that leads to hospitalizations. At this point, patients who are highly susceptible to exacerbations, or at high risk, require individualized discharge and transitional care plans that account for the specific characteristics and severity of their disease.

Hospital-based healthcare providers are extremely well-situated to have a major impact on the care of these patients, not only with direction for appropriate inpatient care of these patients, but also for the direction given at discharge and for transitional care before the patient returns home. With this important responsibility, hospital physicians need to be highly skilled at evaluating patients with COPD based on their risk for recurrent exacerbations and how to tailor their management plan, so patients are put on a path toward successful long-term management of the disease.

Target Audience

This activity has been designed for hospitalists, respiratory therapists, and other healthcare providers involved in the discharge of hospitalized patients with COPD.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Assess future risk for worsening disease and exacerbations in patients with COPD to prevent hospital readmission
  • Provide individualized discharge and transitional care plans for patients at high risk who were recently hospitalized for COPD

Directions to Learner

There are no fees for participating and receiving CME credit for this activity. During the period October 31, 2014 through October 31, 2015, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest by recording the best answer to each question in the answer key on the evaluation form
  • Complete the evaluation form

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be sent to you within 4 weeks.

Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Integrity Continuing Education designates this live activity for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Joshua LaBrin, MD, and Patima Tanapat, PhD, hereby state that they or their spouses/life partners do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sunovion Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc. and Sunovion Pharmaceuticals, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Privacy Policy

When you participate in an online educational activity sponsored by Integrity CE, you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and...(continued)

Minimum System Requirements

Windows XP, Windows 2000, Windows Vista, and Windows 7 Intel Pentium 4, 2.33 + GHz (or equivalent)
Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer is not recommended.

Mac OS X v10.4 or later
1.8GHz or faster (or equivalent)
Intel Core Duo 1.33GHz or faster (or equivalent)
Adobe® Flash® Player 10

Click here for more information on minimum system requirements.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

begin pretest


For optimal performance, the use of Internet Explorer is not recommended.

 Sponsored by Integrity Continuing Education, Inc.
Supported by an educational grant from Sunovion Pharmaceuticals Inc.